C.R. Sincock, MBA
C.R. is an advisor to Orange Grove Bio. He is also the founder and managing partner of Transhuman Capital, a family office venture capital fund focused on early stage biotechnology companies. Transhuman Capital was formed in 2014 when he made the fund's first investment into the seed round of Roivant Sciences, a position that he added to in several follow-on rounds. Roivant strives to “develop transformative medicines faster by building technologies and developing talent in creative ways” - spinoffs from Roivant have led to FDA drug approvals for advanced prostate cancer (ORGOVYX), uterine fibroids (MYFEMBREE), and overactive bladder (Gemtesa). In 2019 C.R. was the founding investor in Kriya Therapeutics, leading the seed round; the fund has subsequently participated in each follow-on round as well. He sits on the board of directors at Kriya, which aims to “revolutionize how gene therapies are designed, developed, and manufactured”. C.R. also sits on the investment advisory board at the University of Michigan Biomedical Venture Fund.
In addition to biotechnology, C.R. has been a longtime entrepreneur and investor in the aviation and energy sectors. He is the CEO of Avflight Corporation and the EVP of Avfuel Corporation. He started his investing career out of college at QVT Financial, a multi-strategy hedge fund based in New York. C.R. graduated magna cum laude and phi beta kappa from Harvard College with a degree in economics and was a Baker Scholar at Harvard Business School where he earned his MBA.